The CAP (Cluster Randomised Trial of PSA testing for Prostate Cancer) trial based on a single PSA screening test failed to show an association between screening and PrCa mortality [6] though as data has matured a modest improvement was shown with screening [7]. Here, KLK3 is linked to pure red-cell aplasia.